JPWO2017020812A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2017020812A5 JPWO2017020812A5 JP2018506197A JP2018506197A JPWO2017020812A5 JP WO2017020812 A5 JPWO2017020812 A5 JP WO2017020812A5 JP 2018506197 A JP2018506197 A JP 2018506197A JP 2018506197 A JP2018506197 A JP 2018506197A JP WO2017020812 A5 JPWO2017020812 A5 JP WO2017020812A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- set forth
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 210000002865 immune cell Anatomy 0.000 claims 16
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 102000010956 Glypican Human genes 0.000 claims 9
- 108050001154 Glypican Proteins 0.000 claims 9
- 108050007237 Glypican-3 Proteins 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 8
- 239000003550 marker Substances 0.000 claims 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 7
- 230000003834 intracellular effect Effects 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 5
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 102000009410 Chemokine receptor Human genes 0.000 claims 2
- 108050000299 Chemokine receptor Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000003812 Interleukin-15 Human genes 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 230000004068 intracellular signaling Effects 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 101150075175 Asgr1 gene Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100024151 Cadherin-16 Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 102000004039 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 102000002029 Claudin Human genes 0.000 claims 1
- 108050009302 Claudin Proteins 0.000 claims 1
- 102100038449 Claudin-6 Human genes 0.000 claims 1
- 108090000229 Claudin-6 Proteins 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- -1 Her3 Proteins 0.000 claims 1
- 102100022132 High affinity immunoglobulin epsilon receptor subunit gamma Human genes 0.000 claims 1
- 108091010847 High affinity immunoglobulin epsilon receptor subunit gamma Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000762246 Homo sapiens Cadherin-16 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 102100023123 Mucin-16 Human genes 0.000 claims 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102000040856 WT1 Human genes 0.000 claims 1
- 108700020467 WT1 Proteins 0.000 claims 1
- 101150084041 WT1 gene Proteins 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108020005243 folate receptor Proteins 0.000 claims 1
- 102000006815 folate receptor Human genes 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 201000003707 ovarian clear cell carcinoma Diseases 0.000 claims 1
- 201000001600 ovarian endodermal sinus tumor Diseases 0.000 claims 1
- 208000030342 ovarian yolk sac tumor Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 230000000890 antigenic effect Effects 0.000 description 2
Description
一つの好適な例において、前記の抗体は、
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、配列番号20で示されるCDR3を有するか、重鎖可変領域が配列番号10で示されるCDR1、配列番号12で示されるCDR2、配列番号14で示されるCDR3を有する抗体(a)（P7D4）、
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、配列番号20で示されるCDR3を有するか、重鎖可変領域が配列番号60で示されるCDR1、配列番号61で示されるCDR2、配列番号14で示されるCDR3を有する抗体(b)（am4）、
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、配列番号20で示されるCDR3を有するか、重鎖可変領域が配列番号62で示されるCDR1、配列番号63で示されるCDR2、配列番号14で示されるCDR3を有する抗体(c)（am14）、
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、配列番号20で示されるCDR3を有するか、重鎖可変領域が配列番号64で示されるCDR1、配列番号65で示されるCDR2、配列番号14で示されるCDR3を有する抗体(d)（am20）、
軽鎖可変領域が配列番号67で示されるCDR1、配列番号68で示されるCDR2、配列番号20で示されるCDR3を有するか、重鎖可変領域が配列番号10で示されるCDR1、配列番号66で示されるCDR2、配列番号14で示されるCDR3を有する抗体(e)（am35）、
軽鎖可変領域が配列番号69で示されるCDR1、配列番号70で示されるCDR2、配列番号20で示されるCDR3を有するか、重鎖可変領域が配列番号10で示されるCDR1、配列番号66で示されるCDR2、配列番号14で示されるCDR3を有する抗体(f)（am42）、
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、配列番号20で示されるCDR3を有するか、重鎖可変領域が配列番号10で示されるCDR1、配列番号71で示されるCDR2、配列番号72で示されるCDR3を有する抗体(g)（T2-23）、
（a）～（g）のうちのいずれかに記載の抗体によって識別される抗原決定基と同様の抗原決定基を識別する抗体（h）、
を含む。
In one preferred embodiment, the antibody comprises:
an antibody (a) (P7D4) having a light chain variable region having CDR1 represented by SEQ ID NO: 16, CDR2 represented by SEQ ID NO: 18, and CDR3 represented by SEQ ID NO: 20, or a heavy chain variable region having CDR1 represented by SEQ ID NO: 10, CDR2 represented by SEQ ID NO: 12, and CDR3 represented by SEQ ID NO: 14;
an antibody (b) (am4) having a light chain variable region having CDR1 represented by SEQ ID NO: 16, CDR2 represented by SEQ ID NO: 18, and CDR3 represented by SEQ ID NO: 20, or a heavy chain variable region having CDR1 represented by SEQ ID NO: 60, CDR2 represented by SEQ ID NO: 61, and CDR3 represented by SEQ ID NO: 14;
an antibody (c) (am14) having a light chain variable region having CDR1 represented by SEQ ID NO: 16, CDR2 represented by SEQ ID NO: 18, and CDR3 represented by SEQ ID NO: 20, or a heavy chain variable region having CDR1 represented by SEQ ID NO: 62, CDR2 represented by SEQ ID NO: 63, and CDR3 represented by SEQ ID NO: 14;
an antibody (d) (am20) having a light chain variable region having CDR1 represented by SEQ ID NO: 16, CDR2 represented by SEQ ID NO: 18, and CDR3 represented by SEQ ID NO: 20, or a heavy chain variable region having CDR1 represented by SEQ ID NO: 64, CDR2 represented by SEQ ID NO: 65, and CDR3 represented by SEQ ID NO: 14;
an antibody (e) (am35) having a light chain variable region having CDR1 represented by SEQ ID NO: 67, CDR2 represented by SEQ ID NO: 68, and CDR3 represented by SEQ ID NO: 20, or a heavy chain variable region having CDR1 represented by SEQ ID NO: 10, CDR2 represented by SEQ ID NO: 66, and CDR3 represented by SEQ ID NO: 14;
an antibody (f) (am42) having a light chain variable region having CDR1 represented by SEQ ID NO: 69, CDR2 represented by SEQ ID NO: 70, and CDR3 represented by SEQ ID NO: 20, or a heavy chain variable region having CDR1 represented by SEQ ID NO: 10, CDR2 represented by SEQ ID NO: 66, and CDR3 represented by SEQ ID NO: 14;
an antibody (g) (T2-23) having a light chain variable region having CDR1 represented by SEQ ID NO: 16, CDR2 represented by SEQ ID NO: 18 , and CDR3 represented by SEQ ID NO: 20, or a heavy chain variable region having CDR1 represented by SEQ ID NO: 10, CDR2 represented by SEQ ID NO: 71, and CDR3 represented by SEQ ID NO: 72;
(h) an antibody that recognizes an antigenic determinant similar to an antigenic determinant recognized by any one of the antibodies (a) to (g);
including.
T2-23のヌクレオチド配列(配列番号34；76～105番目は重鎖CDR1で、148～198番目は重鎖CDR2で、295～330番目は重鎖CDR3で、475～516番目は軽鎖CDR1で、562～582番目は軽鎖CDR2で、679～708番目は軽鎖CDR3である。ここで、1～363番目は重鎖のヌクレオチド配列で、409～741番目は軽鎖のヌクレオチド配列である。364～408番目は(GLY4SER)3連結配列である。
T2-23のアミノ酸配列（配列番号35）：
重鎖CDR1：GFTFSSYAMH (配列番号10)
重鎖CDR2：AISSSGRSTYYADSVEG (配列番号71)
重鎖CDR3：DRRGSHADALNV (配列番号72)
軽鎖CDR1：TGTSSDVGGYNYVS (配列番号16)
軽鎖CDR2：GNSNRPS (配列番号18)
軽鎖CDR3：QSYDSSLRVV (配列番号20)
ここで、1～121番目は重鎖のアミノ酸配列で、137～247番目は軽鎖のアミノ酸配列である。122～136番目は(GLY4SER)3連結配列である。
The nucleotide sequence of T2-23 (SEQ ID NO:34; nucleotides 76-105 are heavy chain CDR1, nucleotides 148-198 are heavy chain CDR2, nucleotides 295-330 are heavy chain CDR3, nucleotides 475-516 are light chain CDR1, nucleotides 562-582 are light chain CDR2, and nucleotides 679-708 are light chain CDR3) (wherein nucleotides 1-363 are the heavy chain nucleotide sequence and nucleotides 409-741 are the light chain nucleotide sequence). nucleotides 364-408 are a (GLY 4 SER) 3 linked sequence).
Amino acid sequence of T2-23 (SEQ ID NO:35):
Heavy chain CDR1: GFTFSSYAMH (SEQ ID NO: 10)
Heavy chain CDR2: AISSSGRSTYYADSVEG (SEQ ID NO:71)
Heavy chain CDR3: DRRGSHADALNV (SEQ ID NO:72)
Light chain CDR1: TGTSSDVGGYNYVS (SEQ ID NO: 16)
Light chain CDR2: GNSNRPS (SEQ ID NO: 18 )
Light chain CDR3: QSYDSSLRVV (SEQ ID NO: 20)
Here, the amino acid sequence of heavy chain is from 1 to 121, and the amino acid sequence of light chain is from 137 to 247. The amino acid sequence of light chain is from 122 to 136, and the (GLY 4 SER) 3 -linked sequence is.
Claims (32)
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、および配列番号20で示されるCDR3を有し、ならびに重鎖可変領域が配列番号10で示されるCDR1、配列番号12で示されるCDR2、および配列番号14で示されるCDR3を有する、抗体(a)；
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、および配列番号20で示されるCDR3を有し、ならびに重鎖可変領域が配列番号60で示されるCDR1、配列番号61で示されるCDR2、および配列番号14で示されるCDR3を有する、抗体(b)；
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、および配列番号20で示されるCDR3を有し、ならびに重鎖可変領域が配列番号62で示されるCDR1、配列番号63で示されるCDR2、および配列番号14で示されるCDR3を有する、抗体(c)；
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、および配列番号20で示されるCDR3を有し、ならびに重鎖可変領域が配列番号64で示されるCDR1、配列番号65で示されるCDR2、および配列番号14で示されるCDR3を有する、抗体(d)；
軽鎖可変領域が配列番号67で示されるCDR1、配列番号68で示されるCDR2、および配列番号20で示されるCDR3を有し、ならびに重鎖可変領域が配列番号10で示されるCDR1、配列番号66で示されるCDR2、および配列番号14で示されるCDR3を有する、抗体(e)；
軽鎖可変領域が配列番号69で示されるCDR1、配列番号70で示されるCDR2、および配列番号20で示されるCDR3を有し、ならびに重鎖可変領域が配列番号10で示されるCDR1、配列番号66で示されるCDR2、および配列番号14で示されるCDR3を有する、抗体(f)；または
軽鎖可変領域が配列番号16で示されるCDR1、配列番号18で示されるCDR2、および配列番号20で示されるCDR3を有し、ならびに重鎖可変領域が配列番号10で示されるCDR1、配列番号71で示されるCDR2、および配列番号72で示されるCDR3を有する、抗体(g)
を含む、前記抗体。 An antibody that specifically recognizes glypican 3, the antibody comprising:
An antibody (a), wherein the light chain variable region has CDR1 set forth in SEQ ID NO: 16, CDR2 set forth in SEQ ID NO: 18, and CDR3 set forth in SEQ ID NO: 20, and the heavy chain variable region has CDR1 set forth in SEQ ID NO: 10, CDR2 set forth in SEQ ID NO: 12, and CDR3 set forth in SEQ ID NO: 14;
An antibody (b) having a light chain variable region having CDR1 set forth in SEQ ID NO: 16, CDR2 set forth in SEQ ID NO: 18, and CDR3 set forth in SEQ ID NO: 20, and a heavy chain variable region having CDR1 set forth in SEQ ID NO: 60, CDR2 set forth in SEQ ID NO: 61, and CDR3 set forth in SEQ ID NO: 14;
An antibody (c) having a light chain variable region having CDR1 set forth in SEQ ID NO: 16, CDR2 set forth in SEQ ID NO: 18, and CDR3 set forth in SEQ ID NO: 20, and a heavy chain variable region having CDR1 set forth in SEQ ID NO: 62, CDR2 set forth in SEQ ID NO: 63, and CDR3 set forth in SEQ ID NO: 14;
An antibody (d) having a light chain variable region having CDR1 set forth in SEQ ID NO: 16, CDR2 set forth in SEQ ID NO: 18, and CDR3 set forth in SEQ ID NO: 20, and a heavy chain variable region having CDR1 set forth in SEQ ID NO: 64, CDR2 set forth in SEQ ID NO: 65, and CDR3 set forth in SEQ ID NO: 14;
An antibody (e) having a light chain variable region having CDR1 set forth in SEQ ID NO: 67, CDR2 set forth in SEQ ID NO: 68, and CDR3 set forth in SEQ ID NO: 20, and a heavy chain variable region having CDR1 set forth in SEQ ID NO: 10, CDR2 set forth in SEQ ID NO: 66, and CDR3 set forth in SEQ ID NO: 14;
An antibody (f) having a light chain variable region with CDR1 set forth in SEQ ID NO: 69, CDR2 set forth in SEQ ID NO: 70, and CDR3 set forth in SEQ ID NO: 20, and a heavy chain variable region with CDR1 set forth in SEQ ID NO: 10, CDR2 set forth in SEQ ID NO: 66, and CDR3 set forth in SEQ ID NO: 14; or an antibody (g) having a light chain variable region with CDR1 set forth in SEQ ID NO: 16, CDR2 set forth in SEQ ID NO: 18 , and CDR3 set forth in SEQ ID NO: 20, and a heavy chain variable region with CDR1 set forth in SEQ ID NO: 10, CDR2 set forth in SEQ ID NO: 71, and CDR3 set forth in SEQ ID NO: 72.
The antibody comprising:
抗体（a）の重鎖可変領域のアミノ酸配列は配列番号4のうちの1～121番目で示され、および前記の抗体の軽鎖可変領域のアミノ酸配列は配列番号4のうちの137～247番目で示されるか；
抗体（b）の重鎖可変領域のアミノ酸配列は配列番号25のうちの1～121番目で示され、および前記の抗体の軽鎖可変領域のアミノ酸配列は配列番号25のうちの137～247番目で示されるか；
抗体（c）の重鎖可変領域のアミノ酸配列は配列番号27のうちの1～121番目で示され、および前記の抗体の軽鎖可変領域のアミノ酸配列は配列番号27のうちの137～247番目で示されるか；
抗体（d）の重鎖可変領域のアミノ酸配列は配列番号29のうちの1～121番目で示され、および前記の抗体の軽鎖可変領域のアミノ酸配列は配列番号29のうちの137～247番目で示されるか；
抗体（e）の重鎖可変領域のアミノ酸配列は配列番号31のうちの1～121番目で示され、および前記の抗体の軽鎖可変領域のアミノ酸配列は配列番号31のうちの137～247番目で示されるか；
抗体（f）の重鎖可変領域のアミノ酸配列は配列番号33のうちの1～121番目で示され、および前記の抗体の軽鎖可変領域のアミノ酸配列は配列番号33のうちの137～247番目で示されるか；または
抗体（g）の重鎖可変領域のアミノ酸配列は配列番号35のうちの1～121番目で示され、および前記の抗体の軽鎖可変領域のアミノ酸配列は配列番号35のうちの137～247番目で示される、
抗体。 2. The antibody of claim 1 ,
the amino acid sequence of the heavy chain variable region of antibody (a) is represented by positions 1 to 121 of SEQ ID NO:4, and the amino acid sequence of the light chain variable region of said antibody is represented by positions 137 to 247 of SEQ ID NO:4;
the amino acid sequence of the heavy chain variable region of antibody (b) is represented by positions 1 to 121 of SEQ ID NO:25, and the amino acid sequence of the light chain variable region of said antibody is represented by positions 137 to 247 of SEQ ID NO:25;
the amino acid sequence of the heavy chain variable region of antibody (c) is set forth in positions 1 to 121 of SEQ ID NO:27, and the amino acid sequence of the light chain variable region of said antibody is set forth in positions 137 to 247 of SEQ ID NO:27;
the amino acid sequence of the heavy chain variable region of antibody (d) is set forth in positions 1 to 121 of SEQ ID NO:29, and the amino acid sequence of the light chain variable region of said antibody is set forth in positions 137 to 247 of SEQ ID NO:29;
the amino acid sequence of the heavy chain variable region of antibody (e) is set forth in positions 1 to 121 of SEQ ID NO:31, and the amino acid sequence of the light chain variable region of said antibody is set forth in positions 137 to 247 of SEQ ID NO:31;
The amino acid sequence of the heavy chain variable region of the antibody (f) is set forth in positions 1 to 121 of SEQ ID NO: 33, and the amino acid sequence of the light chain variable region of the antibody is set forth in positions 137 to 247 of SEQ ID NO: 33; or The amino acid sequence of the heavy chain variable region of the antibody (g) is set forth in positions 1 to 121 of SEQ ID NO: 35, and the amino acid sequence of the light chain variable region of the antibody is set forth in positions 137 to 247 of SEQ ID NO: 35.
antibody.
グリピカン3を発現する腫瘍を診断する試薬の製造、または
キメラ抗原受容体で修飾された免疫細胞の製造における、前記使用。 Use of an antibody according to any one of claims 1 to 6 in the manufacture of a targeted drug, an antibody-drug conjugate or a multifunctional antibody which specifically targets tumor cells expressing glypican 3, or in the manufacture of a reagent for diagnosing tumors expressing glypican 3, or in the manufacture of immune cells modified with a chimeric antigen receptor.
それと連結した、腫瘍表面マーカーを標的とする分子、腫瘍を抑制する分子、免疫細胞の表面マーカーを標的とする分子または検出可能な標識物から選ばれる機能性分子と、
を含む多機能免疫複合体。 An antibody according to any one of claims 1 to 6,
a functional molecule linked thereto, selected from a molecule targeting a tumor surface marker, a molecule suppressing a tumor, a molecule targeting a surface marker of an immune cell, or a detectable label;
A multifunctional immune complex comprising:
前記の腫瘍を抑制する分子は抗腫瘍サイトカインまたは抗腫瘍毒素である、前記多機能免疫複合体。 The multifunctional immunoconjugate of claim 11, wherein the molecule that targets a tumor surface marker is an antibody or ligand that binds to a tumor surface marker, or the tumor-suppressing molecule is an anti-tumor cytokine or an anti-tumor toxin.
免疫細胞の表面マーカーを標的とする分子はT細胞の表面マーカーと結合する抗体で、請求項１～６のいずれか一項に記載の抗体とT細胞が関与する二重機能抗体になることができる、
前記多機能免疫複合体。 The multifunctional immune complex according to claim 11, wherein the detectable label comprises a fluorescent label or a color label, or the molecule targeting the surface marker of an immune cell is an antibody that binds to a surface marker of a T cell, and can be a bifunctional antibody involving the antibody according to any one of claims 1 to 6 and T cells.
The multifunctional immune complex.
免疫細胞の表面マーカーと結合する抗体は抗CD3抗体である、
前記多機能免疫複合体。 The polyfunctional immune complex according to claim 12, wherein the antibody binding to the tumor surface marker is an antibody recognizing an antigen other than glypican 3, said antigen comprising EGFR, EGFRvIII, mesothelin, HER2, EphA2, Her3, EpCAM, MUC1, MUC16, CEA, claudin 18.2, folate receptor, claudin 6, WT1, NY-ESO-1, MAGE 3, ASGPR1 or CDH16, or the antibody binding to the surface marker of immune cells is an anti-CD3 antibody.
The multifunctional immune complex.
グリピカン3を発現する腫瘍を診断する試薬の製造、または
キメラ抗原受容体で修飾された免疫細胞の製造における、前記使用。 Use of a polyfunctional immunoconjugate according to any one of claims 11 to 16 in the manufacture of an antitumor drug, or in the manufacture of a reagent for diagnosing tumors expressing glypican 3, or in the manufacture of immune cells modified with a chimeric antigen receptor.
膜貫通領域はCD8またはCD28の膜貫通領域を含むか、または
キメラ抗原受容体は：
請求項１～６のいずれか一項に記載の抗体、CD8およびCD3ζ；
請求項１～６のいずれか一項に記載の抗体、CD8、CD137およびCD3ζ；
請求項１～６のいずれか一項に記載の抗体、CD28分子の膜貫通領域、CD28分子の細胞内シグナル領域およびCD3ζ；または
請求項１～６のいずれか一項に記載の抗体、CD28分子の膜貫通領域、CD28分子の細胞内シグナル領域、CD137およびCD3ζ；
の順で連結した抗体、膜貫通領域および細胞内シグナル領域を含むか、または
抗体は一本鎖抗体またはドメイン抗体であるか、または
キメラ抗原受容体は：
配列番号49またはそのうちの22～346番目で示されるアミノ酸配列；
配列番号50またはそのうちの22～447番目で示されるアミノ酸配列；
配列番号51またはそのうちの22～491番目で示されるアミノ酸配列；
配列番号52またはそのうちの22～494番目で示されるアミノ酸配列；
配列番号53またはそのうちの22～536番目で示されるアミノ酸配列；
配列番号86で示されるアミノ酸配列；
配列番号88で示されるアミノ酸配列；または
配列番号90で示されるアミノ酸配列を有する、
前記キメラ抗原受容体。 21. The chimeric antigen receptor of claim 20,
The transmembrane domain comprises the transmembrane domain of CD8 or CD28, or the chimeric antigen receptor comprises:
The antibody, CD8 and CD3ζ according to any one of claims 1 to 6;
The antibody, CD8, CD137 and CD3ζ according to any one of claims 1 to 6;
An antibody according to any one of claims 1 to 6, a transmembrane domain of a CD28 molecule, an intracellular signal domain of a CD28 molecule, and CD3ζ; or an antibody according to any one of claims 1 to 6, a transmembrane domain of a CD28 molecule, an intracellular signal domain of a CD28 molecule, CD137, and CD3ζ;
or the antibody is a single chain antibody or a domain antibody; or the chimeric antigen receptor comprises an antibody, a transmembrane domain and an intracellular signal domain linked in the order:
SEQ ID NO: 49 or the amino acid sequence from position 22 to position 346 therein;
SEQ ID NO:50 or the amino acid sequence from 22 to 447 therein;
SEQ ID NO:51 or the amino acid sequence from position 22 to position 491 thereof;
SEQ ID NO:52 or the amino acid sequence from position 22 to position 494 thereof;
SEQ ID NO:53 or the amino acid sequence from position 22 to position 536 thereof;
The amino acid sequence shown in SEQ ID NO:86;
having the amino acid sequence set forth in SEQ ID NO: 88; or having the amino acid sequence set forth in SEQ ID NO: 90.
The chimeric antigen receptor.
請求項２２に記載の核酸、または請求項２３に記載の発現ベクターまたは請求項２４に記載のウイルスを形質導入されているか、あるいは
表面に請求項２０または２１に記載のキメラ抗原受容体が発現されている、
前記免疫細胞。 1. A genetically modified immune cell, comprising:
23. A cell comprising a nucleic acid according to claim 22, an expression vector according to claim 23, or a virus according to claim 24, or expressing a chimeric antigen receptor according to claim 20 or 21 on its surface.
The immune cell.
さらに、外来のサイトカインのコード配列を担持し、または
さらにもう1種類のキメラ抗原受容体を発現し、当該受容体はCD3ζを含まないが、CD28の細胞内シグナルドメイン、CD137の細胞内シグナルドメインまたはこの両者の組み合わせを含むか、または
さらにケモカイン受容体を発現し、または
さらにPD-1の発現を低下させるsiRNAまたはPD-L1を遮断するタンパク質を発現するか、または
さらに安全スイッチを発現し、前記安全スイッチは誘導性カスパーゼ9（iCaspase-9）、短縮型EGFR（Truancated EGFR）またはRQR8を含み、または
免疫細胞はT細胞、NK細胞またはNKT細胞を含む、
前記免疫細胞。 28. The genetically modified immune cell of claim 27,
or expressing a further chimeric antigen receptor, which does not contain CD3ζ but contains the intracellular signaling domain of CD28, the intracellular signaling domain of CD137 or a combination of both; or expressing a chemokine receptor; or expressing an siRNA that reduces expression of PD-1 or a protein that blocks PD-L1; or expressing a safety switch, which safety switch comprises inducible caspase-9 (iCaspase-9), truncated EGFR or RQR8; or the immune cells comprise T cells, NK cells or NKT cells.
The immune cell.
請求項１１～１６のいずれか一項に記載の免疫複合体または当該複合体をコードする核酸、または
請求項２０または２１に記載のキメラ抗原受容体または当該キメラ抗原受容体をコードする核酸、または
請求項２７～３０のいずれか一項に記載の遺伝子修飾された免疫細胞、
を含む薬物組成物。 An antibody according to any one of claims 1 to 6 or a nucleic acid encoding said antibody, or an immune complex according to any one of claims 11 to 16 or a nucleic acid encoding said complex, or a chimeric antigen receptor according to claim 20 or 21 or a nucleic acid encoding said chimeric antigen receptor, or a genetically modified immune cell according to any one of claims 27 to 30,
23. A pharmaceutical composition comprising:
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510481235 | 2015-08-03 | ||
| CN201510481235.1 | 2015-08-03 | ||
| PCT/CN2016/092833 WO2017020812A1 (en) | 2015-08-03 | 2016-08-02 | Antibody against glypican-3 and application thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522564A JP2018522564A (en) | 2018-08-16 |
| JP2018522564A5 JP2018522564A5 (en) | 2019-09-05 |
| JPWO2017020812A5 true JPWO2017020812A5 (en) | 2024-05-13 |
Family
ID=57942442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506197A Pending JP2018522564A (en) | 2015-08-03 | 2016-08-02 | Anti-glypican 3 antibody and use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190046659A1 (en) |
| EP (2) | EP3889184A1 (en) |
| JP (1) | JP2018522564A (en) |
| KR (1) | KR20180054590A (en) |
| CN (2) | CN106397593B (en) |
| AU (1) | AU2016304060B2 (en) |
| BR (1) | BR112018002386A8 (en) |
| CA (1) | CA2994751A1 (en) |
| DK (1) | DK3333192T3 (en) |
| ES (1) | ES2883240T3 (en) |
| HK (1) | HK1251587A1 (en) |
| IL (1) | IL257324B (en) |
| RU (1) | RU2744245C2 (en) |
| SG (1) | SG11201800989RA (en) |
| WO (1) | WO2017020812A1 (en) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE20196219T1 (en) * | 2014-09-26 | 2021-10-28 | Baylor College Of Medicine | Glypican-3-Specific Chimeric Antigen Receptors for Adoptive Immunotherapy |
| TWI759287B (en) * | 2016-03-15 | 2022-04-01 | 日商中外製藥股份有限公司 | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
| EP3445407B1 (en) | 2016-04-22 | 2022-12-14 | CRAGE medical Co., Limited | Compositions and methods of cellular immunotherapy |
| CA3060443A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| CN108866003A (en) * | 2017-05-16 | 2018-11-23 | 科济生物医药（上海）有限公司 | Genetically engineered cell and application |
| CN108853144A (en) * | 2017-05-16 | 2018-11-23 | 科济生物医药（上海）有限公司 | The combination of toll-like receptor agonist and immune effector cell |
| CN107129536A (en) * | 2017-05-24 | 2017-09-05 | 广州市拜沃思生物科技有限公司 | A kind of bispecific antibody and its preparation method and application |
| CN107384949B (en) * | 2017-06-27 | 2019-01-15 | 闾民 | Express iNKT cell and the preparation, application of GPC3 Chimeric antigen receptor |
| CN109385403B (en) * | 2017-08-04 | 2024-03-08 | 恺兴生命科技(上海)有限公司 | GPC 3-targeting CAR NK cells |
| CN109468279A (en) * | 2017-09-08 | 2019-03-15 | 科济生物医药（上海）有限公司 | Target immune effector cell and its application of GPC3 |
| WO2019047932A1 (en) * | 2017-09-08 | 2019-03-14 | 科济生物医药（上海）有限公司 | Genetically engineered t cell and application thereof |
| CN109503715B (en) * | 2017-09-15 | 2023-12-15 | 科济生物医药（上海）有限公司 | Fusion proteins of IL-4R and uses thereof |
| WO2019141270A1 (en) * | 2018-01-19 | 2019-07-25 | 科济生物医药（上海）有限公司 | Synnotch receptor-regulated expression of il12 |
| EP3747433A4 (en) | 2018-02-02 | 2021-12-22 | Cafa Therapeutics Limited | Combination of cellular immunotherapy |
| WO2019170147A1 (en) | 2018-03-09 | 2019-09-12 | 科济生物医药（上海）有限公司 | Method and composition for treating tumors |
| CN112074600A (en) * | 2018-05-03 | 2020-12-11 | 科济生物医药（上海）有限公司 | Immune effector cells and uses thereof |
| CN110438082B (en) * | 2018-05-04 | 2024-03-08 | 恺兴生命科技(上海)有限公司 | Immune effector cells expressing IL-21R binding proteins |
| CN110468105B (en) * | 2018-05-09 | 2024-03-22 | 恺兴生命科技(上海)有限公司 | Immune effector cells expressing IL-18R binding proteins |
| AU2019271819A1 (en) | 2018-05-15 | 2021-01-14 | Crage Medical Co., Limited | Genetically engineered cell and application thereof |
| CN108441505B (en) * | 2018-05-28 | 2023-07-07 | 上海恒润达生生物科技股份有限公司 | Chimeric antigen receptor targeting ROR1 and application thereof |
| CN110577600B (en) * | 2018-06-07 | 2021-05-04 | 中国科学院上海药物研究所 | GPC 3-targeted antibody-drug conjugate, and preparation method and application thereof |
| WO2020020210A1 (en) | 2018-07-24 | 2020-01-30 | 科济生物医药（上海）有限公司 | Method for treating tumor using immune effector cell |
| CN110760005A (en) * | 2018-07-25 | 2020-02-07 | 上海细胞治疗集团有限公司 | Chimeric antigen receptor modified T cell of targeted Glypican-3 antigen and application thereof |
| CN109021108B (en) * | 2018-08-27 | 2019-06-25 | 南京医科大学 | The full humanized antibody of resisting GPC 3, its Chimeric antigen receptor cell and application |
| US20230416385A1 (en) * | 2018-11-01 | 2023-12-28 | Shandong New Time Pharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
| CN113164408A (en) | 2018-12-07 | 2021-07-23 | 科济生物医药（上海）有限公司 | Tumor combined immunotherapy |
| WO2020118634A1 (en) * | 2018-12-13 | 2020-06-18 | 科济生物医药（上海）有限公司 | Immune effector cell targeting gpc3 and application thereof |
| JP2022524906A (en) | 2019-01-07 | 2022-05-11 | クレージュ メディカル カンパニー，リミテッド | Combination of cell immunotherapy |
| EP3883971A1 (en) * | 2019-01-22 | 2021-09-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
| EP3919517A4 (en) * | 2019-02-01 | 2023-03-15 | CRAGE medical Co., Limited | Tcr fusion protein and cell expressing tcr fusion protein |
| CN113891897A (en) * | 2019-03-21 | 2022-01-04 | 新加坡科技研究局 | Composition comprising a metal oxide and a metal oxide |
| WO2020219715A1 (en) * | 2019-04-23 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | A dota-binding chimeric antigen receptor for cellular therapy |
| WO2021110095A1 (en) * | 2019-12-05 | 2021-06-10 | 上海翰森生物医药科技有限公司 | Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof |
| CN111187351B (en) * | 2020-04-14 | 2020-08-04 | 浙江恒驭生物科技有限公司 | Liver cancer detection kit |
| CN115298216A (en) * | 2020-04-20 | 2022-11-04 | 上海翰森生物医药科技有限公司 | Antibody or antigen binding fragment thereof, preparation method and medical application thereof |
| US20230310600A1 (en) | 2020-08-07 | 2023-10-05 | Crage Medical Co., Limited | Engineered cells and method for engineering cells |
| KR20220080381A (en) * | 2020-12-07 | 2022-06-14 | (주)이노베이션바이오 | Antibody specific for GPC3 and uses thereof |
| WO2022171100A1 (en) * | 2021-02-10 | 2022-08-18 | 江苏先声药业有限公司 | Humanized gpc3 antibody and application thereof |
| CN117545771A (en) | 2021-04-08 | 2024-02-09 | 克莱格医学有限公司 | Application of cellular immunotherapy |
| CN117480247A (en) * | 2021-04-15 | 2024-01-30 | 恺兴生命科技(上海)有限公司 | Chimeric T cell receptor and uses thereof |
| WO2023274303A1 (en) | 2021-06-29 | 2023-01-05 | 科济生物医药（上海）有限公司 | Chimeric polypeptide for regulating cell physiological activity |
| CN113527500B (en) * | 2021-07-16 | 2022-09-20 | 蒋小滔 | Fully human monoclonal antibody of glypican 3, chimeric antigen receptor and application thereof |
| CN113354737B (en) * | 2021-07-20 | 2022-11-18 | 广州爱思迈生物医药科技有限公司 | Glypican 3 antibody and application thereof |
| WO2023023354A2 (en) * | 2021-08-19 | 2023-02-23 | Adicet Therapeutics, Inc. | Methods for detection of membrane bound glypican-3 |
| CN114539410B (en) * | 2022-03-15 | 2023-09-05 | 苏州量化细胞生物科技有限公司 | CLDN18.2 binding antibodies, probes and use in single cell sequencing of CLDN18.2 expressing cells |
| WO2023207475A1 (en) * | 2022-04-24 | 2023-11-02 | 昱言科技(北京)有限公司 | Monoclonal antibody targeting gpc3 and antibody-drug conjugate comprising same |
| WO2024067764A1 (en) * | 2022-09-30 | 2024-04-04 | 信立泰(成都)生物技术有限公司 | Anti-gpc3 monoclonal antibody/bispecific antibody or antigen-binding fragment thereof and use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2208784B1 (en) * | 2001-06-22 | 2013-01-02 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican 3 antibody |
| WO2004022597A1 (en) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
| US7883853B2 (en) * | 2002-05-23 | 2011-02-08 | Sunnybrook Health Sciences Centre | Diagnosis of hepatocellular carcinoma |
| JP4011100B2 (en) * | 2004-07-09 | 2007-11-21 | 中外製薬株式会社 | Anti-glypican 3 antibody |
| AU2005297772B2 (en) * | 2004-10-26 | 2011-06-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having modified sugar chain |
| US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| ES2373069T3 (en) | 2006-08-11 | 2012-01-31 | Schering Corporation | ANTIBODIES FOR IL-17A. |
| US8680247B2 (en) * | 2007-07-17 | 2014-03-25 | Medarex, L.L.C. | Monoclonal antibodies against glypican-3 |
| CL2009000647A1 (en) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject. |
| CN101633693A (en) * | 2009-08-24 | 2010-01-27 | 中国人民解放军第二军医大学 | Monoclonal antibody for resisting GPC3 |
| CN105968209B (en) * | 2011-04-19 | 2021-08-03 | 美国政府(由卫生和人类服务部的部长所代表) | Human monoclonal antibodies specific for glypican 3 and uses thereof |
| WO2013070468A1 (en) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| CN102634486B (en) * | 2012-03-28 | 2014-12-10 | 南方医科大学 | GPC3 (glypican-3) monoclonal antibody hybridoma cell strain 7D11 and preparation method and application thereof |
| CN103833852A (en) * | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | Bispecific antibody aiming at phosphatidylinositols protein polysaccharide-3 and T cell antigen |
| TWI693073B (en) * | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients |
| CN104140974B (en) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | Encode the nucleic acid of the Chimeric antigen receptor albumen of GPC 3 and express the T lymphocytes of the Chimeric antigen receptor albumen of GPC 3 |
| CN108884459B (en) * | 2016-04-26 | 2024-04-02 | 科济生物医药（上海）有限公司 | Method for improving immune response cell function |
-
2016
- 2016-08-02 JP JP2018506197A patent/JP2018522564A/en active Pending
- 2016-08-02 SG SG11201800989RA patent/SG11201800989RA/en unknown
- 2016-08-02 DK DK16832300.4T patent/DK3333192T3/en active
- 2016-08-02 BR BR112018002386A patent/BR112018002386A8/en active Search and Examination
- 2016-08-02 AU AU2016304060A patent/AU2016304060B2/en active Active
- 2016-08-02 IL IL257324A patent/IL257324B/en unknown
- 2016-08-02 KR KR1020187006248A patent/KR20180054590A/en not_active Application Discontinuation
- 2016-08-02 ES ES16832300T patent/ES2883240T3/en active Active
- 2016-08-02 CA CA2994751A patent/CA2994751A1/en active Pending
- 2016-08-02 RU RU2018105963A patent/RU2744245C2/en active
- 2016-08-02 US US15/750,271 patent/US20190046659A1/en active Pending
- 2016-08-02 CN CN201610626384.7A patent/CN106397593B/en active Active
- 2016-08-02 WO PCT/CN2016/092833 patent/WO2017020812A1/en active Application Filing
- 2016-08-02 EP EP21168464.2A patent/EP3889184A1/en active Pending
- 2016-08-02 CN CN201910736574.8A patent/CN111018986B/en active Active
- 2016-08-02 EP EP16832300.4A patent/EP3333192B1/en active Active
-
2018
- 2018-08-24 HK HK18110961.4A patent/HK1251587A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2017020812A5 (en) | ||
| JP2018522564A5 (en) | ||
| JP2018529327A5 (en) | ||
| RU2018105963A (en) | ANTIBODY AGAINST GLIPICAN-3 AND ITS APPLICATION | |
| RU2018107802A (en) | COMPLETELY HUMAN ANTIBODIES TO MESOTELIN AND IMMUNE EFFECTIVE CELLS AIMED AT MESOTELIN | |
| JP2019523630A5 (en) | ||
| RU2018104703A (en) | TUMOR-SPECIFIC ANTIBODY AGAINST EGFR AND ITS APPLICATION | |
| JP2021502104A5 (en) | ||
| JP2019525771A5 (en) | ||
| JP2018528786A5 (en) | ||
| RU2018139339A (en) | NEW SPECIFIC POLYPEPTIDES AGAINST CD137 | |
| KR20230098158A (en) | Humanized Antibodies Targeting CD7 and Uses Thereof | |
| JP2015527070A5 (en) | ||
| KR20190139909A (en) | Anti-PD-L1 / anti-PD-1 native antibody structure-like heterodimer bispecific antibodies and preparations thereof | |
| WO2022152168A1 (en) | Ror1-targeting antibody and use thereof | |
| TWI806961B (en) | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same | |
| EP2838557A1 (en) | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity | |
| JP2018526033A5 (en) | ||
| JP2020516681A5 (en) | ||
| CN115996946A (en) | Activatable IL2 compositions and methods of use | |
| CN112638950A (en) | Bispecific antibody | |
| WO2022247795A1 (en) | Nanobody targeting claudin18.2 and use thereof | |
| Schaedel et al. | Antibodies and their fragments as anti-cancer agents | |
| WO2021027785A1 (en) | Immune effector cell for co-expressing chemokine receptor | |
| WO2022222910A1 (en) | Gprc5d-targeting antibody and use thereof |